home / stock / achv / achv news

ACHV News and Press, Achieve Life Sciences Inc. From 03/16/23

Stock Information
Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com
Menu
ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHV - Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, tod...
ACHV - Achieve Life Sciences Q4 2022 Earnings Preview

2023-03-15 17:35:43 ET Achieve Life Sciences ( NASDAQ: ACHV ) is scheduled to announce Q4 earnings results on Thursday, March 16th, after market close. The consensus EPS Estimate is -$0.95 and the consensus Revenue Estimate is $0.08M Over the last 3 months, EPS estimat...

ACHV - Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, tod...

ACHV - Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

SEATTLE, Wash. and VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, ann...
ACHV - Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023

SEATTLE, Wash and VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, to...

ACHV - Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, toda...

ACHV - Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference

SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, toda...
ACHV - Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug

Summary ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase 3 ORCA-3 registration trial is ongoing, and we expect the data readout in 2Q 2023; we expect the results to be positive. The ...

ACHV - Achieve Life Sciences Announces Granting of New Hire Inducement Award

SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announc...

ACHV - Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, tod...
Previous 10 Next 10